Hong Kong, 19 March 2026 — China Resources Pharmaceutical Group Limited (stock code: 03320, “CHINARES PHARMA”) disclosed the audited results of its Shanghai-listed subsidiary, China Resources Jiangzhong Pharmaceutical Co., Ltd. (“CR Jiangzhong”), for the year ended 31 December 2025.

Key FY 2025 Financial Highlights (PRC GAAP) • Total assets rose 5.73% year on year to RMB6.88 billion (2024: RMB6.51 billion). • Net assets attributable to CR Jiangzhong shareholders increased 4.14% to RMB4.02 billion (2024: RMB3.86 billion).

Profitability and Cash Flow • Revenue declined 4.87% to RMB4.22 billion (2024: RMB4.44 billion). • Net profit attributable to shareholders climbed 15.03% to RMB906.69 million (2024: RMB788.19 million). • Profit excluding extraordinary items reached RMB833.26 million, up 11.22% from RMB749.18 million a year earlier. • Net operating cash inflow expanded 23.48% to RMB970.87 million (2024: RMB786.25 million).

Per-Share Metrics • Basic and diluted earnings per share were both RMB1.43, up 14.40% from RMB1.25 in 2024. • Weighted average return on equity improved by 3.17 percentage points to 22.75%.

Dividend Proposal CR Jiangzhong’s board recommends a cash dividend of RMB8.80 (tax inclusive) for every 10 shares, subject to approval at the 2025 annual general meeting.

Shareholding Structure CHINARES PHARMA, through its non-wholly-owned subsidiary China Resources Jiangzhong Pharmaceutical Group Co., Ltd., holds an effective 26.12% interest in CR Jiangzhong, which continues to be consolidated as a subsidiary.

Investors are advised to refer to CR Jiangzhong’s full 2025 annual report available on the Shanghai Stock Exchange website for comprehensive details. The financial data above relate solely to CR Jiangzhong and do not represent the consolidated results of CHINARES PHARMA.